SCHEMBL29607136

SCHEMBL29607136

COc1cc(C=O)cc(OCCN(C)C(=O)OC(C)(C)C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.45
PPARG P37231 2/20 0.38
PPARD Q03181 2/20 0.38
PPARA Q07869 2/20 0.38
FFAR1 O14842 1/20 0.38
MAOB P27338 5/20 0.38
MAOA P21397 3/20 0.38
DRD2 P14416 1/20 0.36
HDAC3 O15379 1/20 0.35
STAT3 P40763 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31192642 0.89 PDK2 (0.43) PDK2PPARGPPARDPPARAFFAR1
SCHEMBL29606221 0.83 PDK2 (0.53) PDK2MAOBMAOALMNA
SCHEMBL14262633 0.82 PDK2 (0.51) PDK2PPARAMAOBDRD2KAT6A
SCHEMBL21601541 0.80 PDK2 (0.54) PDK2PPARADRD2
SCHEMBL29606706 0.79 PDK2 (0.46) PDK2STAT3KAT6AKAT5
SCHEMBL29608210 0.79 PDK2 (0.48) PDK2KAT6AKAT5
SCHEMBL29607734 0.79 FDPS (0.59) LMNA
SCHEMBL29606344 0.79 FDPS (0.52) PDK2LMNA
SCHEMBL7956465 0.79 MAOB (0.52) MAOBMAOAAHR
SCHEMBL29607003 0.78 MAOB (0.52) PDK2MAOBDRD2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEIGENE, LTD. (KY) 2025-04-22 US disclosed
EP-3921320-B1 IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEIGENE LTD (KY) 2024-03-06 EP disclosed
US-20220119394-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEONE MEDICINES I GMBH (CH) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119394-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST TLR7, TLR1, TLR3 PDK2 3792/4885PPARG 290/4885PPARD 342/4885
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR1, TLR3 PDK2 3792/4885PPARG 290/4885PPARD 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.